SUWANEE, GA, Jan. 26, 2018 (GLOBE NEWSWIRE) --
SANUWAVE Health, Inc. (OTCQB: SNWV), announced today that the Company’s CEO and Board of Directors Chairman, Kevin A. Richardson II will be in attendance at the Anti-Biofilm Technologies: Pathways to Product Development Conference in Washington DC, on February 6-7, 2018. This conference is organized by the Center for Biofilm Engineering from Montana State University, the leading research organization in biofilms’ studies.
This year’s meeting will feature speakers from industry, academia, and regulatory agencies focusing on new anti-biofilm technologies, methods for assessing their efficacy, and how these advances can lead to products to the enhancement of health and safety. The main sessions of the conference will focus on Medical Device Technologies and Surface Disinfection Technologies used for medical and industrial biofilms. A panel discussion will follow each session.
“This represents a great opportunity for SANUWAVE to understand the latest progress in anti-biofilm technologies and the methods used for biofilm testing. Also, with the presence at this conference of representatives from the Food and Drug Administration (FDA) and Environmental Protection Agency (EPA), we will be able to better understand the regulatory processes and the level of proof necessary for approval of medical and non-medical devices used for eliminating biofilms. Moreover, by comparing SANUWAVE’s technology with other technologies used for biofilm reduction or elimination, we will be able to identify new applications of our shock wave technology for specific industrial or medical biofilms. Finally, we will be able to begin exploring strategic partnerships in the biofilm arena, which represents a significant market opportunity for the Company,” commented Kevin A. Richardson II, Chairman of the board of directors of SANUWAVE.
SANUWAVE Health Inc., and its wholly owned subsidiary SANUWAVE, Inc., now have 68 patents (issued or pending) in the field of shock waves used in medical and non-medical applications.
About the Center for Biofilm Engineering
Montana State University's Center for Biofilm Engineering has been a world leader in biofilm research for more than 20 years. A prestigious 11-year National Science Foundation Engineering Research Center grant awarded in 1990 paved the way for the CBE's influence in the emerging field of biofilm research. The Center's three-fold emphasis in research, education, and industry continues to produce results and exciting opportunities for students, staff, and faculty—as well as industrial partners.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors, or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.